Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The enzyme CARM1 (coactivator-associated arginine methyltransferase 1) is a key transcriptional coactivator involved in various biological processes.
• Dysregulated CARM1 expression is linked to the progression of several cancer types, making it a significant therapeutic target.

Purpose of the Study:

• To identify and develop novel, potent inhibitors of CARM1.
• To evaluate the efficacy of these inhibitors in preclinical cancer models, focusing on solid tumors and immuno-oncology.

Main Methods:

• Structure-based drug design was employed to discover a series of N1-(3-(pyrimidin-2-yl)benzyl)ethane-1,2-diamine compounds.
• Compound 43 was selected for further evaluation due to its high potency and selectivity.
• In vivo efficacy studies were conducted using solid tumor models, including immuno-oncology assessments in MC38 C57BL/6J xenografts.

Main Results:

• A novel series of CARM1 inhibitors was successfully synthesized and characterized.
• Compound 43 exhibited high potency and selectivity for CARM1.
• Compound 43 demonstrated excellent tissue distribution and significant in vivo efficacy against solid tumors.
• Immuno-oncology studies revealed that compound 43 profoundly impacts tumor immunity.

Conclusions:

• The discovered CARM1 inhibitors, particularly compound 43, represent promising therapeutic agents for solid tumor treatment.
• Compound 43's ability to modulate tumor immunity opens new possibilities for cancer immunotherapy strategies.
• Targeting arginine post-translational modification via CARM1 inhibition is a viable approach for future cancer therapies.